Ultragenyx Pharmaceutical Inc. (RARE) Financial Statements (2024 and earlier)

Company Profile

Business Address 60 LEVERONI COURT
NOVATO, CA 94949
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments577,209747,762740,1961,201,533755,230459,706
Cash and cash equivalents213,584132,944307,584713,526433,584113,432
Short-term investments363,625614,818432,612488,007321,646346,274
Restricted cash and investments  862 10,847161271
Receivables73,39040,44528,43223,09332,84412,740
Inventory, net of allowances, customer advances and progress billings33,96926,76616,23113,04811,5467,065
Inventory33,96926,76616,23113,04811,5467,065
Other current assets47,616     
Other undisclosed current assets  68,06471,74546,78351,23642,587
Total current assets:732,184883,899856,6041,295,304851,017522,369
Noncurrent Assets
Operating lease, right-of-use asset  25,96134,93640,52430,328
Property, plant and equipment290,566259,726141,24773,51544,34820,046
Long-term investments and receivables199,901148,970258,93310,5065,174 
Long-term investments199,901148,970258,93310,5065,174 
Intangible assets, net (including goodwill)210,677204,511175,194175,519173,406173,629
Goodwill44,40644,40644,40644,40644,40644,406
Intangible assets, net (excluding goodwill)166,271160,105130,788131,113129,000129,223
Restricted cash and investments  3,7952,0011,9212,499 
Other noncurrent assets57,68516,84620,5588,8123,4713,514
Other undisclosed noncurrent assets  1,73632,924153,45425,253 
Total noncurrent assets:758,829661,545665,793464,251284,479197,189
TOTAL ASSETS:1,491,0131,545,4441,522,3971,759,5551,135,496719,558
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities238,600247,952162,693121,41496,06574,725
Accounts payable42,11443,27417,13812,92312,87112,275
Accrued liabilities196,486204,678145,555108,49183,19462,450
Deferred revenue   9,07666,568 
Debt  1835684607,235 
Other undisclosed current liabilities41,83713,0759,0311,167  
Total current liabilities:280,437261,210181,368189,609103,30074,725
Noncurrent Liabilities
Long-term debt and lease obligation   30,90439,25129,757 
Finance lease, liability   410701 
Liabilities, other than long-term debt72,83756,30134,31133,306 35,925
Deferred tax liabilities, net31,166
Deferred income tax liabilities30,05831,66733,30633,306 
Other liabilities12,2054,8201,005  4,759
Operating lease, liability 30,57419,81430,49438,55029,757
Other undisclosed noncurrent liabilities862,325875,439353,253343,014348,675 
Total noncurrent liabilities:935,162931,740418,468415,571378,43235,925
Total liabilities:1,215,5991,192,950599,836605,180481,732110,650
Equity
Equity, attributable to parent275,414352,494922,5611,154,375653,764608,908
Common stock827069675851
Treasury stock, value(432)     
Additional paid in capital3,662,3463,140,0192,997,4972,773,1952,086,8631,639,773
Deferred employee stock ownership plan, issuance of shares or sale of treasury shares432     
Accumulated other comprehensive income (loss)647(6,573)(1,404)689(147)(633)
Accumulated deficit(3,387,661)(2,781,022)(2,073,601)(1,619,576)(1,433,010)(1,030,283)
Total equity:275,414352,494922,5611,154,375653,764608,908
TOTAL LIABILITIES AND EQUITY:1,491,0131,545,4441,522,3971,759,5551,135,496719,558

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues434,249363,329351,406271,030103,71451,495
Cost of revenue
(Cost of Goods and Services Sold)
      (1,146)
Gross profit:434,249363,329351,406271,030103,71450,349
Operating expenses(958,248)(983,928)(717,135)(601,146)(527,887)(422,868)
Other undisclosed operating income (loss)(45,209)(28,320)(16,008)  1,146
Operating loss:(569,208)(648,919)(381,737)(330,116)(424,173)(371,373)
Nonoperating income26,3519,5082417,64512,4513,954
Investment income, nonoperating26,68811,0741,9287,03813,2389,542
Other nonoperating income (expense)(337)(1,566)(1,687)607(787)(5,588)
Interest and debt expense  (37)(58)(40)  
Loss from continuing operations before equity method investments, income taxes:(542,857)(639,448)(381,554)(322,511)(411,722)(367,419)
Other undisclosed income (loss) from continuing operations before income taxes(65,607)(62,277)(71,427)137,15212,278170,322
Loss from continuing operations before income taxes:(608,464)(701,725)(452,981)(185,359)(399,444)(197,097)
Income tax expense (benefit)1,825(5,696)(1,044)(1,207)(3,283)(514)
Loss from continuing operations:(606,639)(707,421)(454,025)(186,566)(402,727)(197,611)
Loss before gain (loss) on sale of properties:(454,025)(186,566)(402,727)(197,611)
Net loss available to common stockholders, diluted:(606,639)(707,421)(454,025)(186,566)(402,727)(197,611)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(606,639)(707,421)(454,025)(186,566)(402,727)(197,611)
Other comprehensive income (loss)7,220(5,169)(2,093)8364865,047
Comprehensive loss, net of tax, attributable to parent:(599,419)(712,590)(456,118)(185,730)(402,241)(192,564)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: